Date | Company | Who recommends | Recommendation | Target price |
---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | Argus | Buy | 155 | |
Amgen Inc. | Deutsche Bank | Buy | 180 | |
Anthem, Inc. | RBC Capital Mkts | Buy | 198 | |
Universal Health Services Inc. | Barclays | Buy | 150 | |
Allergan plc | Deutsche Bank | Buy | 342 | |
Boston Scientific Corporation | Deutsche Bank | Buy | 22 | |
HCA Holdings, Inc. | UBS | Buy | 90 | |
Pfizer Inc. | Morgan Stanley | Buy | 43 | |
AbbVie Inc. | UBS | Buy | 78 | |
Biogen Inc. | Bernstein | Buy | 360 | |
Gilead Sciences Inc. | Deutsche Bank | Buy | 124 | |
Bristol-Myers Squibb Company | Morgan Stanley | Buy | 80 | |
DENTSPLY International Inc. | Morgan Stanley | Buy | 70 | |
Edwards Lifesciences Corp. | RBC Capital Mkts | Buy | 160 | |
Merck & Co. Inc. | UBS | Buy | 68 | |
St. Jude Medical Inc. | Deutsche Bank | Buy | 77 | |
Stryker Corporation | Argus | Buy | 120 | |
Mallinckrodt Public Limited Company | Barclays | Buy | 80 | |
Abbott Laboratories | Barclays | Buy | 52 | |
DaVita HealthCare Partners Inc. | RBC Capital Mkts | Buy | 83 |